Lot of people in there for a short term profit of course. It is in the interest for any big pharma to sit and wait until lots of good news equates to an excellent outcome - while IMU is funding the research.
Inevitably, "spec" biotech shares will be seen as undervalued regarding their potential. An excellent outcome in the phase 2 trial will change that equation.
New investor pres with B-vaxx update, page-37
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
